UPDATE: Allergan (AGN) Tops Q3 EPS by 9c

(Updated - November 1, 2017 7:09 AM EDT)

Allergan (NYSE: AGN) reported Q3 EPS of $4.15, $0.09 better than the analyst estimate of $4.06. Revenue for the quarter came in at $4.03 billion versus the consensus estimate of $4.03 billion.

It sees FY EPS of $16.15 - $16.45 vs consensus of $16.20 and GAAP revenue of $15.88-$16.03 billion vs consensus of $15.89 billion.

For earnings history and earnings-related data on Allergan (AGN) click here.

You May Also Be Interested In

• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
• Home Depot beats estimates, reaffirms fiscal 2026 guidance